PDL BIOPHARMA INC's ticker is and the CUSIP is 69329YAG9. A total of 16 filers reported holding PDL BIOPHARMA INC in Q1 2017. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $11,153,000 | -33.3% | 10,624,000 | -27.4% | 0.39% | -22.6% |
| Q1 2019 | $16,726,000 | -6.5% | 14,624,000 | -17.2% | 0.51% | -36.8% |
| Q4 2018 | $17,890,000 | -16.4% | 17,666,000 | -18.5% | 0.81% | +23.8% |
| Q3 2018 | $21,396,000 | +5.1% | 21,681,000 | -2.3% | 0.65% | -1.1% |
| Q2 2018 | $20,365,000 | -7.7% | 22,181,000 | +2.3% | 0.66% | +0.5% |
| Q1 2018 | $22,074,000 | +5.2% | 21,684,000 | -0.6% | 0.66% | +10.8% |
| Q4 2017 | $20,973,000 | -13.3% | 21,804,000 | -2.3% | 0.59% | -16.5% |
| Q3 2017 | $24,177,000 | +6.7% | 22,309,000 | -11.4% | 0.71% | -22.4% |
| Q2 2017 | $22,663,000 | +26.4% | 25,181,000 | +23.1% | 0.91% | +31.8% |
| Q1 2017 | $17,928,000 | -20.2% | 20,461,000 | -26.8% | 0.69% | -21.9% |
| Q4 2016 | $22,456,000 | – | 27,961,000 | – | 0.89% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SMH CAPITAL ADVISORS INC | 12,804,000 | $12,636,000 | 21.66% |
| Context Partners Fund, L.P. | 7,175,000 | $7,034,000 | 4.09% |
| Context Capital Management, LLC | 7,175,000 | $7,034,000 | 4.09% |
| Pinnacle Holdings, LLC | 3,260,000 | $3,217,213,000 | 1.11% |
| Venator Capital Management Ltd. | 2,000,000 | $1,960,000 | 0.98% |
| LINDEN ADVISORS LP | 26,617,000 | $26,292,000 | 0.80% |
| WHITEBOX ADVISORS LLC | 21,681,000 | $21,396,000 | 0.65% |
| WOLVERINE ASSET MANAGEMENT LLC | 16,852,000 | $16,518,000 | 0.19% |
| OAKTREE CAPITAL MANAGEMENT LP | 4,695,000 | $4,657,000 | 0.06% |
| AQR Arbitrage LLC | 3,150,000 | $3,124,000 | 0.04% |